By Colin Kellaher

 

AbbVie Inc. (ABBV) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of a shorter Maviret treatment duration in certain patients with chronic hepatitis C.

The North Chicago, Ill., biopharmaceutical company said the CHMP's positive opinion covers shortening the once-daily treatment duration to eight weeks from 12 in treatment-naive, compensated cirrhotic, chronic hepatitis C patients with genotype 3 infection.

AbbVie said the change, if approved by the European Commission, will make Maviret the only pan-genotypic eight-week treatment option for treatment-naive chronic hepatitis C patients, without cirrhosis or with compensated cirrhosis.

The EC, which generally follows the CHMP's recommendations, is expected make a decision this year, AbbVie said.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

January 31, 2020 07:50 ET (12:50 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more AbbVie Charts.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more AbbVie Charts.